Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in Untreated Locally Advanced dMMR/MSI-H Rectal Cancer
NCT05723562Phase 2Active, not recruiting
- Sponsor
- GSK
- Start
- Apr 2023
- Primary completion
- Nov 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 10
01
Overview
A Phase 2 trial of dostarlimab in rectal cancer, sponsored by GSK. Started Apr 2023; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT05723562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05723562.